10-Q: HeartBeam Reports Q3 2026 Results, Faces Going Concern Doubt

HeartBeam, Inc. filed its Q3 2026 10-Q, detailing continued operational losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern, though it achieved key regulatory milestones.

Summary

• HeartBeam, Inc. reported its quarterly results for the period ending September 30, 2026.
• The company continues to incur losses, with a net loss of $3.01 million for the three months ended September 30, 2026, and $12.75 million for the nine months ended September 30, 2026.
• As of September 30, 2026, the company had $6.1 million in cash and cash equivalents, which is deemed insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company received FDA Breakthrough Device Designation for Heart Attack Assessment on October 5, 2026.
• HeartBeam also joined the European EXIT-CVD Research Consortium and announced the completion of enrollment in the HEADSTART-ACS study ahead of schedule.
• The company's common stock bid price fell below $1.00, leading to a Nasdaq deficiency letter, with a compliance period until December 28, 2026.
• Operating expenses decreased year-over-year for the three-month period but increased for the nine-month period, primarily due to changes in stock-based compensation and headcount.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued net losses, substantial doubt about its ability to continue as a going concern, and a Nasdaq bid price deficiency, despite positive clinical and regulatory developments.

Positives

• Received FDA Breakthrough Device Designation for Heart Attack Assessment on October 5, 2026, which provides prioritized FDA review and interaction.
• Joined the European EXIT-CVD Research Consortium to advance at-home ECG monitoring.
• Completed enrollment in the HEADSTART-ACS study ahead of schedule, enrolling 486 patients.
• The ALIGN-ACS pilot study showed HeartBeam's 3D ECG technology to be as accurate as the standard 12-Lead ECG, with higher specificity (81.8% vs. 71.4%).
• 100% of patients in the ALIGN-ACS study successfully recorded their own ECGs with the HeartBeam device.
• Accepted into the FDA's Total Product Life Cycle Advisory Program (TAP) to accelerate patient access to devices.
• Secured $13.1 million in gross proceeds from equity offerings and ATM sales during the first nine months of 2026.
• Strengthened intellectual property portfolio with new U.S. patent for acoustic sensing and fluid monitoring capabilities.

Negatives

• The company has incurred losses each year since inception and has experienced negative cash flows from operations.
• As of September 30, 2026, the company's liquidity is insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Received a Nasdaq deficiency letter on June 30, 2026, due to the common stock bid price falling below $1.00 per share, with a compliance deadline of December 28, 2026.
• Net loss for the three months ended September 30, 2026, was $3.01 million, and $12.75 million for the nine months ended September 30, 2026.
• Selling, general, and administrative expenses increased by 12% for the nine months ended September 30, 2026, compared to the prior year, primarily due to stock-based compensation.
• Research and development expenses decreased significantly, partly due to the completion of product development and pilot studies, indicating a shift in focus or resource allocation.

Risks

• The company's existing liquidity is insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting, materially adversely affecting liquidity and the ability to raise capital.
• Management can provide no assurance that additional financing or strategic relationships will be available on acceptable terms, or at all.
• The company is subject to risks common to early-stage companies, including dependence on key individuals, difficulties in commercial market development, and competition.
• The company has not generated material commercial revenue and does not expect to in 2026.
• The company's ability to achieve its long-term vision depends on successful development and commercialization of its technology, including expanded indications for heart attack detection.

Future Outlook

The company believes its existing liquidity is insufficient to fund operations for the next twelve months and its continued operations depend on its ability to raise additional capital. It does not expect material commercial revenue in 2026. The company is focused on advancing its clinical and regulatory program towards an expanded indication for heart attack detection and intends to strike a balance in managing headcount in line with cash resources.

Management Comments

• "Based on the current business plan assumptions, existing financing arrangements and expected cash burn rate, the Company believes that its existing liquidity is insufficient to fund operations for the next twelve months following the issuance of these financial statements."
• "Management believes the continued achievement of these milestones will provide the Company the ability to raise additional capital. However, management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which if not consummated would likely have a material adverse effect on the Company and its financial statements."
• "We believe that our system records the most info-rich ambulatory ECG signal available, enabled by our patented 3D signal technology."
• "The Company is focused on rapidly advancing the clinical and regulatory program towards an expanded indication for heart attack detection."
• "We believe that a few well-placed resources will help provide the data points required to effectively invest into a broader launch based around a path to profitable growth."

Industry Context

StockSavvy.ai notes that HeartBeam operates in the rapidly growing field of ambulatory cardiac monitoring, a market estimated at $40 billion. The company's focus on transforming cardiac care with personalized insights and higher-resolution ECG solutions positions it within a competitive landscape that includes larger companies and other technology providers. The recent FDA Breakthrough Device Designation for heart attack assessment is a significant step towards addressing a larger market opportunity estimated at $15 billion.

Comparison to Industry Standards

• The ALIGN-ACS pilot study demonstrated HeartBeam's 3D ECG technology to be as accurate as the standard 12-Lead ECG in ischemia detection, with higher specificity (81.8% vs. 71.4%) and comparable sensitivity.
• HeartBeam ECGs were interpreted more consistently across cardiologists than standard 12-lead ECGs in the ALIGN-ACS study.
• The company's technology aims to provide higher-fidelity data collection for arrhythmia assessment compared to single-lead or 6-lead consumer devices.
• The company is pursuing an expansion for heart attack detection, a market opportunity four times larger than the arrhythmia market, addressing the critical need for timely treatment when time is critical.

Legal Proceedings

• There are no actions, suits, proceedings, inquiries or investigations pending or threatened against the Company, its common stock, or its officers or directors in which an adverse decision could have a material adverse effect.

Related Party Transactions

• Accounts payable includes $5,000 related to a director for the period ended September 30, 2026.
• Accrued expenses includes $5,000 related to a director for the period ended September 30, 2026.
• The company entered into a consulting agreement with an independent director for business development services, paying $5,000 per month and granting 70,000 options.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq if bid price compliance is not regained, impacting stock liquidity and ability to raise capital. Continued dilution from ATM offerings.
• Creditors: Substantial doubt about going concern raises concerns about the company's ability to meet its financial obligations.
• Employees: Management intends to balance headcount with cash resources, suggesting potential hiring constraints or workforce management.
• Customers/Patients: Potential for improved cardiac care through advanced monitoring solutions if the company achieves commercial success and regulatory approvals.

Next Steps

• Seek FDA alignment on the design of a multicenter pivotal study for heart attack assessment in the coming months.
• Anticipate beginning patient enrollment in the pivotal study shortly after FDA alignment.
• Continue limited commercial launch to validate real-world performance and establish reference sites for broader commercialization.
• Develop real-world evidence and clinical validation to support a scalable go-to-market strategy for the MI Detection market.
• Monitor the closing bid price of its common stock and evaluate available options to regain compliance with Nasdaq listing rules within the prescribed timeframe.

Key Dates

Recommendation

The company faces significant financial headwinds, including insufficient liquidity to fund operations for the next twelve months, raising substantial doubt about its going concern status. The Nasdaq bid price deficiency poses a material risk of delisting, which would severely impact its ability to raise capital. While there are positive clinical and regulatory developments, these do not outweigh the immediate financial and listing risks. Therefore, a sell recommendation is warranted.

Keywords

Cardiac Monitoring, ECG, Heart Attack Detection, Arrhythmia, FDA, Medical Technology, Startup, Biotech